©The Author(s) 2025.
World J Gastrointest Oncol. Nov 15, 2025; 17(11): 113431
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.113431
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.113431
Table 1 Patient characteristics, mean ± SD/median (interquartile ranges)
| Characteristics | Number of patients |
| HCC | |
| Age, years | 56.2 ± 12.3 |
| Sex | |
| Male | 92 |
| Female | 15 |
| Tumor size (mm) | 6.26 ± 4.1 |
| Tumor stage | |
| BCLC-A | 37 |
| BCLC-B | 41 |
| BCLC-C | 39 |
| Vascular invasion | |
| Macro invasion | 20 |
| Micro invasion | 15 |
| No invasion | 72 |
| Before treatment | 84 |
| After R0 resection | 14 |
| After conservative treatment | 9 |
| Benign disease | |
| Age | 54.3 (25-70) |
| Histological type | |
| Liver cirrhosis | 7 |
| Hemangioma | 10 |
| Hepatolithiasis | 4 |
- Citation: Zhang ZY, Zhou M, Liu JJ, Zhang W. Folate receptor-positive circulating tumor cells might function as potential biomarkers for hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(11): 113431
- URL: https://www.wjgnet.com/1948-5204/full/v17/i11/113431.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i11.113431